America based Gilead Sciences Inc. stock slipped 0.75% to $68.77 Friday. This proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.19% to 4,247.44 and the Dow Jones Industrial Average DJIA rising 0.04% to 34,479.60.
Gilead Sciences Inc. closed $10.17 short of its 52-week high ($78.94), which the company reached on July 20th. The stock demonstrated a mixed performance when compared to some of its competitors Friday, as Johnson & Johnson JNJ fell 1.27% to $164.96, Merck & Co. Inc. MRK rose 0.17% to $76.27, and AbbVie Inc. ABBV fell 0.71% to $115.42.
Analysts expect GILD to post earnings of $1.74 per share. This would mark year-over-year growth of 56.76%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $6.15 billion, up 19.57% from the year-ago period.GILD’s full-year Zacks Consensus Estimates are calling for earnings of $7.07 per share and revenue of $24.74 billion. These results would represent year-over-year changes of -0.28% and +0.22%, respectively.